Double blind, randomized, placebo controlled clinical trial for the treatment of diabetic foot ulcers, using a nitric oxide releasing patch: PATHON by Silva, Sandra Y et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Trials
Open Access Study protocol
Double blind, randomized, placebo controlled clinical trial for the 
treatment of diabetic foot ulcers, using a nitric oxide releasing 
patch: PATHON
Sandra Y Silva1, Ligia C Rueda1, Gustavo A Márquez1, Marcos López2, 
Daniel J Smith2, Carlos A Calderón3, Juan C Castillo1, Jaime Matute4, 
Christian F Rueda-Clausen1, Arturo Orduz1, Federico A Silva1, 
Piyaporn Kampeerapappun2, Mahesh Bhide2 and Patricio López-
Jaramillo*1,5
Address: 1VILANO Group. Research Institute, Fundación Cardiovascular de Colombia (FCV), Floridablanca, Santander, Colombia, 2Department 
of Chemistry, University of Akron, Akron, Ohio, USA, 3Fundación Santandereana de Diabetes y Obesidad (FUSANDE), Bucaramanga, Santander, 
Colombia, 4Instituto de Seguros Sociales, Bucaramanga, Santander, Colombia and 5Facultad de Medicina, Universidad de Santander, 
Bucaramanga, Santander, Colombia
Email: Sandra Y Silva - sandrasilvac@gmail.com; Ligia C Rueda - ligiarueda62@gmail.com; Gustavo A Márquez - piedegus@yahoo.es; 
Marcos López - marcoslopez@mcw.edu; Daniel J Smith - djs5@uakron.edu; Carlos A Calderón - calderindicor@hotmail.com; 
Juan C Castillo - juancarcastillo@latinmail.com; Jaime Matute - matutejaime42@yahoo.com; Christian F Rueda-
Clausen - ruedaclausen@gmail.com; Arturo Orduz - aorduz@cable.net.co; Federico A Silva - fsilva5@hotmail.com; 
Piyaporn Kampeerapappun - st_bernard75@hotmail.com; Mahesh Bhide - maheshswara@yahoo.com; Patricio López-
Jaramillo* - jplopezj@hotmail.com
* Corresponding author    
Abstract
Background: Diabetes Mellitus constitutes one of the most important public health problems due
to its high prevalence and enormous social and economic consequences. Diabetic foot ulcers are
one of the chronic complications of diabetes mellitus and constitute the most important cause of
non-traumatic amputation of inferior limbs. It is estimated that 15% of the diabetic population will
develop an ulcer sometime in their lives. Although novel therapies have been proposed, there is no
effective treatment for this pathology. Naturally produced nitric oxide participates in the wound
healing process by stimulating the synthesis of collagen, triggering the release of chemotactic
cytokines, increasing blood vessels permeability, promoting angiogenic activity, stimulating the
release of epidermical growth factors, and by interfering with the bacterial mitochondrial
respiratory chain. Topically administered nitric oxide has demonstrated to be effective and safe for
the treatment of chronic ulcers secondary to cutaneous leishmaniasis. However, due to their
unstable nitric oxide release, the topical donors needed to be applied frequently, diminishing the
adherence to the treatment. This difficulty has led to the development of a multilayer polymeric
transdermal patch produced by electrospinning technique that guarantees a constant nitric oxide
release. The main objective of this study is to evaluate the effectiveness and safety of this novel
nitric oxide releasing wound dressing for the treatment of diabetic foot ulcers.
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Methods and design: A double-blind, placebo-controlled clinical trial, including 100 diabetic
patients was designed. At the time of enrollment, a complete medical evaluation and laboratory
tests will be performed, and those patients who meet the inclusion criteria randomly assigned to
one of two groups. Over the course of 90 days group 1 will receive active patches and group 2
placebo patches. The patients will be seen by the research group at least every two weeks until the
healing of the ulcer or the end of the treatment. During each visit the healing process of the ulcer,
the patient's health status and the presence of adverse events will be assessed. Should the
effectiveness of the patches be demonstrated an alternative treatment would then be available to
patients.
Trial registration: NCT00428727.
Background
Diabetes Mellitus (DM) constitutes one of the most
important public health problems with a worldwide
impact due to its high prevalence and enormous social
and economic consequences. It is believed that there are
more than 135 million diabetics, and this number is
expected to increase to 300 million in the next 25 years
(30% in developed and 70% in developing countries)
[1,2].
This epidemic is related to several factors like ethnicity,
the longer life expectancy, and the epidemiological and
nutritional transition in developing countries due to the
urbanization process that brings about obesity and seden-
tarism [3,4]. In Colombia, the 2002 basic health indica-
tors showed a 2% prevalence of DM. However, it is
believed that these numbers are underestimated [5]. Dia-
betic Foot Ulcers (DFU) are one of the chronic conse-
quences of DM which constitute the most important
cause of non-traumatic amputation of the Inferior Limbs
(IL), and are associated with high human, social and eco-
nomic costs [6-11]. It is estimated that approximately
15% of the diabetic population will develop a DFU some
time in their life [12-16].
DFU is a consequence of two of the most frequent chronic
complications of DM: Peripheral neuropathy and vascular
insufficiency [12]. The combination of these factors in
association with mechanic extrinsic and intrinsic aggres-
sions, like feet bone deformations, triggers the ulcer for-
mation. This polyfactorial etiopathology explains the
multidisciplinary approach required for this disease [17-
19].
The early detection of risk factors for DFU may prevent
their appearance [20-28]. This is why the monitoring of
neuropathic, vascular and muscle-skeletal functions [29],
the reinforcement of self care [30], the control of glycemic
levels and the prevention of traumatic foot lesions
[21,23,24,31], have a positive impact on the prevention of
this pathology.
The wound healing process involves the interaction of
multiple cellular groups, extra cellular matrix molecules
and growth factors [32], and is affected by vascular insuf-
ficiency, the severity of the lesion and the presence of
infection [18,24].
Immune and wound healing mechanism dysfunctions
have been described in diabetic patients [33]. This altera-
tion of the immune response is characterized by a
decrease in the adherence of leukocytes to the capillary
endothelium, chemotaxis damage and a reduction in the
ability of polymorphonuclear cells to phagocyte and
destroy bacteria due to a minor production of Nitric
Oxide (NO) [34,35]. Diabetic patients also show a dimi-
nution in fibroblasts activity provoked by the unavailabil-
ity of glucose for the aerobic metabolism, leading to
inadequate fibrous collagen tissue proliferation [36]. The
imbalance in these processes has been described as the
main cause for the appearance and persistence of DFU
[37].
Alternative therapies for DFU have been proposed, such as
tissue engineering [38], growth factors [39], hyperbaric
oxygen therapy [40,41] and ketanserine [42,43]. Various
types of products have also been used to keep the wound
dry and covered (hydrogels, hydrocolloids, alginates and
foams) [44], however, there is no effective treatment for
this pathology [45,46].
In normal conditions, NO is continuously produced [47]
and is tightly linked to many physiological processes,
among which wound healing. It has been described that
NO stimulates collagen synthesis [48], triggers the release
of chemotactic cytokines [49], and has an important
microbicidal effect by interfering with the enzymatic proc-
esses of the bacterial mitochondrial respiratory chain [50].
It also increases blood vessels permeability [51-54], pro-
motes angiogenic activity, and stimulates the release of
epidermical growth factors [37,55].
Various studies, performed in murine models, have dem-
onstrated the role of NO in the healing process. The levelsTrials 2007, 8:26 http://www.trialsjournal.com/content/8/1/26
Page 3 of 8
(page number not for citation purposes)
of the final metabolic products from NO (nitrite and
nitrate) rise during the first two days more than subse-
quently in the liquid recovered from the sponges previ-
ously placed in the subcutaneous tissue of healthy
subjects' wounds [56], increase that is not observed in dia-
betic subjects [54], suggesting an impairment in the cuta-
neous production of NO in diabetic individuals. The
topical use of NO accelerates the wound healing process
of excisional wounds [54,57] while NO inhibitors
increase the healing time of these lesions [48,58]. The use
of colloid NO donors in diabetic subjects shows an ade-
quate granulation and closing of wounds [59,60].
Our experience in the treatment of cutaneous leishmania-
sis with s-nitroso-N-acetilpenicilamine (SNAP), a NO
donor, shows a beneficial effect without adverse events
[61]. Moreover, a clinical trial is being conducted to study
the effectiveness of a controlled NO releasing patch in the
treatment of cutaneous leishmaniasis [62]. Currently,
there are no studies using topical NO donors in humans
with diabetic ulcers. Though the use of NO donors in
healthy volunteers has shown an adequate NO diffusion
rate to dermis, and an increase in the microcapillar blood
flow [63], this method has demonstrated not to be effec-
tive due to the short half life and release span of NO [61].
This difficulty in controlling the stability and release of
NO has led to the development of a new NO releasing
patch (NOP). This device, produced by the electrospin-
ning technique [64], is a multilayer polymeric transder-
mal patch in which the principal components are
stabilized and encapsulated in nanofibers which guaran-
tees a constant NO release upon its hydration.
Since it is well known that the system generates NO
almost immediately, nitrite ions are bound to an ionic
exchange resin (DOWEX®) in order to stabilize them,
allowing a constant release of 3.5 µmol of NO during 12
hours or more depending upon the dosage [64]. This
device has been tested by our group for the treatment of
cutaneous leishmaniasis obtaining encouraging results in
the healing process with no report of serious adverse
events [61]. Since there is no specific effective treatment
for DFU our group proposes to investigate the topical use
of NOP, elaborated by the electrospinning technique, for
the treatment of DFU.
Objectives
General Objective
To evaluate the effectiveness and safety of NOP for the
treatment of DFU.
Specific Objectives
1. To evaluate the healing process of DFU using a NOP
compared with placebo.
2. To assess the healing process of infected DFU using a
NOP compared with placebo.
3. To identify adverse events associated with the applica-
tion of NOP.
Methods and design
Double blind, randomized, placebo controlled clinical
trial.
Sample size
The sample was calculated according to the arccosine for-
mula considering a power of 80% and a type I error of
0.05. Assigning a successful rate of 30% in the control
group and 60% in the active group, 95 participants will be
needed. After adjusting for a loss rate of 5%, the total
number of patients that must be recruited is 100 (50
patients per group).
Population
The population will be composed of patients with a con-
firmed diagnosis of DM type 1 or 2 who present DFU,
meet the inclusion criteria and don't present any criterion
that could exclude them.
Inclusion criteria
1. Men and women 18 years or older.
2. Capacity of attending the visits at the research site.
3. Confirmed diagnosis of DM type 1 or 2 according to the
guidelines from the American Diabetes Association
(ADA).
4. Presence of 1 or more DFU, less than 15 cm in its big-
gest diameter, with a Texas University score ≤ 2.
5. Pharmacological treatment for glycemic control.
6. Willingness to participate in the study and to sign the
informed consent form.
Exclusion criteria
1. Unconfirmed DM diagnosis.
2. Any pathology that, based on the judgment of the
researcher, could alter the course of DFU (neoplasias,
immunological disorders, etc).
3. Renal insufficiency requiring dialysis treatment.
4. DFU with aTexas score >2.
5. Infected DFU with clinical or paraclinical findings sug-
gesting osteomielytis.Trials 2007, 8:26 http://www.trialsjournal.com/content/8/1/26
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6. Critical ischemia of IL diagnosed by Doppler ultra-
sound and defined by ankle/arm index < 0.5.
7. Clinical findings suggesting complicated venous insuf-
ficiency of IL.
8. Distal necrosis of the limb with the ulcer.
9. Pregnant or breastfeeding women.
10. Mentally or neurologically disabled patients that are
considered not fit to approve their participation in the
study.
11. Refusal to give informed consent.
Study development
See table 1.
Logistic phase
This phase will be managed by the physician in charge of
the study and a professional nurse and will include the
following activities.
1. Acquisition of the materials required for the develop-
ment of the project.
2. Elaboration of flyers, promotional and educative mate-
rial, procedures manual and Case Report Format (CRF).
4. Training of personnel that will participate in the study.
5. Treatment randomization
The treatment randomization will be realized by the epi-
demiologist of the Fundación Cardiovascular de Colom-
bia (FCV). This randomization will be done in blocks in
order to avoid long sequences of patients assigned to the
same group and to reduce when possible, some of the bias
inherent to the simple randomization process. Addition-
ally, this randomization in blocks will facilitate the execu-
tion of interim analyses.
Recruitment phase
Patients will attend the screening visit at the FCV or at the
offices of the physicians involved in the study.
Screening visit
During this visit a complete medical check-up, based on
universally accepted techniques, will evaluate risk factors,
DM complications, vascular and neuropathic compro-
mise, medications and other therapies used for the treat-
ment of DFU. The ankle/arm index will be obtained to
rule out the presence of critical IL ischemia. The inclusion/
exclusion criteria will be applied and the selected candi-
dates informed about the study after which they will sign
an informed consent form. A blood sample will be with-
drawn to determine the percentage of glycosilated hemo-
globin (HbA1c), the levels of creatinine and fasting
glucose, the hemogram, and the lipid profile.
The laboratory of the Research Institute of FCV and the
laboratories of every other center will be in charge of the
Table 1: Schedule of activities
Follow-up visits
PROTOCOL ACTIVITIES Screening Visit Initial Visit Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Final Visit
SCHEDULE OF VISITS 0 15 ± 5 30 ± 5 45 ± 5 60 ± 5 75 ± 5 90 ± 5
Clinical History X X X X X X X X
Physical Examination X X X X X X X X
Inclusion/Exclusion criteria X
Informed Consent X
Clinical assessment of vascular 
compromise
X X XXXXX X
Clinical assessment of neuropathic 
compromise
XX
Laboratory tests X X
Ankle/arm index X
Randomization X
Treatment administration X X X X X X
Clinical assessment of the lesion X X X X X X X X
Measurement of ulcers X X X X X X X X
Photographic registration X X X X X X X
Education of patients X X X X X X X X
Documentation of adverse events X X X X X X X X
Recording of concomitant 
medications
X X XXXXX XTrials 2007, 8:26 http://www.trialsjournal.com/content/8/1/26
Page 5 of 8
(page number not for citation purposes)
processing of blood samples. All the tests will be elabo-
rated using standard techniques.
1. Glycosilated hemoglobin: Chromatography.
2. Creatinine: Spectrophotometry.
3. Hemogram: Manual method.
4. Lipid profile: Spectrophotometry.
5. Fasting glucose: Spectrophotometry.
Initial visit
The selected patients will be scheduled for the initial visit.
In this visit the patients will be randomly assigned to one
of the two groups. Group 1 will receive NOP and Group 2
placebo patches. A complete medical evaluation will be
performed, the ulcers measured, and their pictures taken.
Neuropathy will be assessed using the modified validated
neuropathic impairment score (NDS) [65]. Before taking
the pictures, a graduated ruler will be placed next to the
ulcers with a sticker marked with the identification code
of the participant and the date of the visit. The first patch
(active or placebo) will be applied on the lesion. All the
information obtained will be registered in the CRFs. The
treatment previously prescribed for DM or other concom-
itant pathologies, and the medical, surgical or orthopedic
therapies for DFU will be continued with the exception of
topical treatment. The researchers will follow the guide-
lines of the International Diabetic Foot Consensus
(CIPD). The patient and his/her family will receive infor-
mation regarding the treatment of DFU, the correct tech-
nique for the daily application of the patches and the
identification and notification of adverse events.
Follow-up visits
The treatment will last 90 days. During this period, the
patients will be seen by the research group at least every
two weeks until the healing of the ulcer or the end of the
treatment. The frequency of the visits will vary depending
on the clinical evolution of the patients. During each visit
the healing process of the ulcer, the patient's health status
and the presence of adverse events will be assessed. The
patch will be applied and the evolution of the ulcers pho-
tographically registered. The maximum and minimum
diameters of the ulcer will be measured using a graduated
ruler and then registered in the CRF. The technique for the
application of the patches, the identification of adverse
events and the importance of reporting them, will be
emphasized.
Final visit
The final visit will take place at the end of the treatment or
before in case of complete healing of the ulcer. A thorough
medical evaluation, including laboratory tests will be per-
formed along with the assessment of vascular and neuro-
pathic compromise. The presence of adverse events will
also be evaluated. The evolution of the ulcers will be doc-
umented by measuring their maximum and minimum
diameters and by photographing them.
National Coordination from Monitoring Center
Every six months a researcher from FCV will visit each
center to evaluate the fulfillment of the protocol and the
accomplishment of the Good Clinical Practice.
Data base depuration phase
After completing all the data entry to the CRF the results
will be audited and the detected errors evaluated and cor-
rected. The information will be entered in two different
databases by two different people and the records com-
pared to detect any discrepancy using a statistical software
(Epi-Info 6.04). The mistakes will be corrected according
to the CRF, and the corrections registered.
Each patient will be identified using an internal code. All
the photographs will be processed using a digital edition
software.
Statistical analysis
For the statistical analysis, Stata 8.0 will be used. The
descriptive analysis will be composed of medians and
proportions according to the nature of the variables, with
their respective 95% confidence intervals. As a dispersion
measurement the standard deviation will be calculated.
The distribution of the variables will be studied using the
Shapiro-Wilk test and the homocedasticity of the vari-
ances with the Levene test. To detect any difference
between the groups, a T-test or a Mann Whitney test will
be performed according to the distribution of the varia-
bles. The categorical variables will be compared using the
Chi2 test or the exact Fisher's test. If required, a model of
multiple logistic regressions or a covariance analysis will
be realized. Two interim analyses will be performed when
35 and 70% of the total sample is collected to determine
differences in effectiveness and safety between the groups.
Endpoints
At the end of the treatment the following endpoints will
be evaluated:
1. Ulcer reduction percentage.
2. Complete cure of the infection that was present before
the treatment.
3. Infection of the ulcers during the treatment.Trials 2007, 8:26 http://www.trialsjournal.com/content/8/1/26
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4. Presence of adverse events related to the application of
the patches.
Final report
The results of the study will be evaluated and discussed
and a final report presented to the Federación Diabetológ-
ica Colombiana (FDC), entity that is sponsoring the
project. The results will be submitted for publication and
presented in congresses and scientific meetings.
Ethical aspects
This study will be conducted in accordance with the Dec-
laration of Helsinki and with the Colombian legislation
as per the Resolution 8430/93 from the Ministry of
Health. Prior to the admission of the patients in the study,
the objectives and the methodology will be explained and
a written informed consent obtained. The study was
approved by the Research Ethic Committee of the FCV
(Act# 075/April 27/2004). The patients' right to confiden-
tiality will be maintained in all the phases of the study.
Evaluation and management of adverse events
During the visits the patients will be asked about adverse
events. Each adverse event will be classified by the physi-
cian as serious or non-serious. A serious adverse event
should meet one or more of the following criteria:
1. Death
2. Life-threatening
3. Hospitalization or prolongation of existing hospitaliza-
tion
4. Persistent or significant disability/incapacity
The presence of a serious adverse event that puts the
patient's life at risk and/or requires immediate medical or
surgical procedure will call for the discontinuation of the
treatment and the initiation of the pertinent medical man-
agement. The investigator will notify the Adverse Event
Committee (AEC) of the FCV of any serious adverse event
within 24 hours of learning about it.
A non-serious adverse event will be classified as follows:
1. Mild: The patient is aware of his/her symptoms and/or
signs, but those are tolerable. Medical intervention or spe-
cific treatment is not required.
2. Moderate: The patients present troubles that interfere
with his/her daily activities. Medical intervention or spe-
cific treatment is required.
3. Severe: The patient is unable to work or to attend his/
her daily activities. Medical intervention or specific treat-
ment is required.
The possible relationship between the adverse events and
the tested medication will be classified by the investigator
on the basis of his/her clinical judgment and the follow-
ing definitions:
1. Definitely related: Event can be fully explained by the
administration of the tested medication.
2. Probably related: Event is most likely to be explained by
the administration of the tested medication rather than
other medications or by the patient's clinical state.
3. Possibly related: Event may be explained by the admin-
istration of the tested medication or other medications or
by the patient's clinical state.
4. Not related: Event is most likely to be explained by the
patient's clinical state or by the use of other medications,
rather than the tested one.
All the events will be reported to the AEC that, depending
on its criteria, will decide the continuity of the patient in
the study and therefore the breaking of the code. Although
the project has been designed to minimize the inherent
risks, any adverse event related to the study medication
will be carefully evaluated by the AEC and the costs gener-
ated by the required treatment covered by the study.
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